Several cytochrome P450 (CYP) enzymes are expressed in the human lung, where they participate in metabolic inactivation and activation of numerous exogenous and endogenous compounds. In this study, the expression pattern of all known xenobiotic-metabolizing CYP genes was characterized in the human alveolar type II cell-derived A549 adenocarcinoma cell line using qualitative reverse transcriptase/polymerase chain reaction (RT-PCR). In addition, the mechanisms of induction by chemicals of members in the CYP1 and CYP3A subfamilies were assessed by quantitative RT-PCR. The expression of messenger RNAs (mRNAs) of CYPs 1A1, 1B1, 2B6, 2C, 2E1, 3A5, and 3A7 was detected in the A549 cells. The amounts of mRNAs of CYPs 1A2, 2A6, 2A7, 2A13, 2F1, 3A4, and 4B1 were below the limit of detection. 2,3,7,8-tetrachlorodibenzo-p -dioxin (TCDD) induced CYP1A1 and CYP1B1 mRNAs 56-fold and 2.5-fold, respectively. CYP3A5 was induced 8-fold by dexamethasone and 11-fold by phenobarbital. CYP3A4 was not induced by any of the typical CYP3A4 inducers used. The tyrosine kinase inhibitor genistein and the protein kinase C inhibitor staurosporine blocked TCDD-elicited induction of CYP1A1, but they did not affect CYP1B1 induction. Protein phosphatase inhibitors okadaic acid and calyculin A enhanced TCDD-induction of CYP1B1 slightly, but had negligible effects on CYP1A1 induction. These results suggest that CYP1A1 and CYP1B1 are differentially regulated in human pulmonary epithelial cells and give the first indication of the induction of CYP3A5 by glucocorticoids in human lung cells. These results establish that having retained several characteristics of human lung epithelial cell CYP expression, the A549 lung cell line is a valuable model for mechanistic studies on induction of the pulmonary CYP system. 
The lung constitutes a primary site of exposure for many inhaled chemical toxicants and carcinogens. As a consequence, the lung represents a major target for chemically induced diseases such as lung cancer, as well as parenchymal and obstructive lung diseases. Many of the hazardous chemicals, including constituents of cigarette smoke, are not active as such but require an enzymatic biotransformation to reactive forms (1) . Attention has been primarily focused on cytochrome P450 (CYP)-dependent phase I activation of procarcinogens (2) . Variations in the level of expression of this enzyme system have been implicated as being partly responsible for the interindividual differences in susceptibility to a multitude of cancers, including lung cancer (3, 4) .
Lung tissues are known to activate several procarcinogens, such as the polycyclic aromatic hydrocarbon benzo-( a )pyrene (B[ a ]P), and several N -nitrosamines to form DNA adducts (5) . It was shown recently (6) that benzo( a )pyrene diol epoxide, the ultimate carcinogenic metabolite of B( a )P, causes lung cancer-specific mutations in the p53 tumor suppressor gene in human bronchial epithelial cells, thus providing a direct link between lung cancer and B( a )P exposure. CYP enzymes taking part in the activation of B( a )P include several individual forms in families CYP1 and CYP3A (1) . These CYP forms are expressed in various human pulmonary cell types. The main target of lung cancer caused by tobacco, the bronchial epithelial cells, expresses CYP1A1 (7) (8) (9) (10) (11) (12) (13) and CYP1B1 (10, 11) , and these CYP forms are inducible by cigarette smoking. In addition, airway epithelial cells contain CYP3A5 messenger RNA (mRNA) and protein (12, 14, 15) . Thus, the human lung tis-sue has the capacity to activate carcinogens and other toxins, and it is likely that factors affecting the activity of pulmonary CYPs may influence the risk of acquiring lung cancer and other chemically caused pulmonary diseases.
The induction of CYP enzymes in different human tissues is well characterized (16, 17) . Induction of CYP1A1 and CYP3A4 by a variety of chemicals has been most intensively studied. Enzyme induction in the human lung has been less thoroughly studied, but we know that CYP1A1 and CYP1B1 induction occurs in response to cigarette smoking (7) (8) (9) 11) . CYP3A enzymes are apparently not induced in human lung by cigarette smoke (15) , and CYP3A5, the major pulmonary CYP3A form, is thought to be noninducible in the liver (18, 19) .
The study on in vivo CYP induction in the human lung is technically demanding and requires the collection of lung biopsies or airway epithelial cell samples. Alternatively, surrogate cells such as alveolar macrophages can be used, but it is obvious that such surrogate cells do not accurately reflect the behavior of the actual target cells. To obtain insight into the mechanisms of human lung CYP induction, ex vivo models are needed. Primary cultures of bronchial epithelial cells and immortalized epithelial cells have been used, but these systems have a finite life span and show phenotypic alterations during subculturing. Transformed lung epithelial cell lines have been widely used, and one such continuous cell line, the alveolar epithelial type II cell-derived lung adenocarcinoma cell line A549 (20) , has been a popular model. The A549 cells have retained some metabolic capacities of the normal type II alveolar cells, such as expressing CYP1A1, CYP1B1, and CYP2B6 (21, 22) and having the capability of forming DNA adducts after B( a )P treatment (23) . This cell line thus provides a promising model for study of the regulation of human pulmonary epithelial cell CYP enzymes.
In this study, we have characterized in the A549 cell line the expression pattern of all known xenobiotic-metabolizing CYP genes. In addition, the induction profile caused by chemicals of members in the CYP1 and CYP3 families was determined. The results show that the A549 cell line is especially well suited for studying the control of expression of xenobiotic-metabolizing CYPs in the human lung because this cell line expresses most of the major constitutive and inducible CYP forms found in lung epithelial cells.
Materials and Methods

Reagents
2,3,7,8-tetrachlorodibenzo-p -dioxin (TCDD) was obtained from the National Cancer Institute Chemical Carcinogen Repository (Bethesda, MD). Rifampicin, dexamethasone, phenobarbital, pregnenolone 16 ␣ -carbonitrile, and clotrimazole were purchased from Sigma (St. Louis, MO). Okadaic acid, calyculin A, staurosporine, and genistein were purchased from Calbiochem (La Jolla, CA).
Cell Culture
The human lung adenocarcinoma cell line A549, originally from the American Type Culture Collection (Rockville, MD), was cultured in Ham's F12 medium with L -glutamine (GIBCO BRL, Grand Island, NY) supplemented with 10% fetal bovine serum (GIBCO BRL) and 10 g/ml gentamicin (GIBCO BRL). The cells were cultured at 37 Њ C, 5% CO 2 , and saturated humidity. Nearly confluent cells were incubated for 24 h in the presence of inducers (10 M rifampicin, 10 M dexamethasone, 1.5 mM phenobarbital, 10 nM TCDD, 10 M PCN, or 10 M clotrimazole). Modulators of TCDD induction (10 nM okadaic acid, 3 nM calyculin A, 50 M genistein, or 50 nM staurosporine) were added together with TCDD. Control cultures received the same concentration of vehicle (0.5% dimethyl sulfoxide). After the incubation, cells were washed with phosphate-buffered saline (pH 7.4), suspended in the same buffer, and centrifuged. The cell pellet was suspended in cell lysis buffer for mRNA extraction. The inducer and modulator concentrations used were not cytotoxic judged from cell morphology and ␤ -actin mRNA contents of the cells. In pilot experiments, a range of inducer and modulator concentrations were tested. The concentrations chosen for the actual studies were the ones causing maximal induction or inhibition without any signs of cytotoxicity.
mRNA and Complementary DNA
The mRNA of A549 cells was extracted with QuickPrep Micro mRNA Purification Kit (Amersham Pharmacia Biotech, Uppsala, Sweden). The extraction of human liver and alveolar macrophage mRNAs used as positive controls have been described previously (24) . To remove contaminating genomic DNA, mRNA preparations were treated with RNase-free DNase I and the DNase was removed by phenol/chloroform/isoamyl alcohol extraction. Complementary DNA (cDNA) was synthesized with the First-Strand Synthesis Kit (Amersham Pharmacia Biotech). All reagents were from Amersham Pharmacia Biotech. Human liver and human alveolar macrophage cDNAs used as positive controls were prepared the same way as mentioned previously for A549 cells.
RNA Blot Analysis
The amount and the integrity of mRNA in every sample were verified with conventional RNA (Northern) blot analysis. An aliquot of mRNA was electrophoresed in an agarose gel and transferred to Hybond-N ϩ nylon filter (Amersham, Buckinghamshire, UK) followed by hybridization with [ In every series of PCRs was a negative control containing an aliquot of cDNA synthesis reaction performed with heat-inactivated reverse transcriptase enzyme. All PCRs were repeated at least twice. The primers were designed to be gene specific, except CYP2C primers, which detected all known human CYP2C forms (i.e., 2C8, 2C9, 2C18, and 2C19). To exclude chances of cross-hybridization with other sequences, each primer was compared with the European Molecular Biology Laboratory human gene bank using the FASTA program (Genetics Computer Group, Madison, WI). The primers were also designed to amplify regions containing at least one intron in the gene to exclude contamination of cDNA with genomic DNA. Because the genomic structure of CYP1B1 was not available at the time of the design of the primers, we were unable to target the CYP1B1 primers to separate exons. The primers, their locations, and the sizes of the PCR products were described previously (25) (26) (27) (28) . After the PCR, an 8-l aliquot of each reaction mixture was electrophoresed in an agarose gel and stained with ethidium bromide. A visible band of the correct size was considered a sign of the specific mRNA being present in the sample.
Quantitative RT-PCR
Competitive PCR controls for CYP1A1, CYP1B1, CYP3A4, and CYP3A5 were prepared according to Jin and coworkers (29) . The basis of this method is PCR amplification of a part of the target sequence with the same 3 Ј primer and a recombinant 5 Ј primer to produce a shortened template that can be amplified by the original primer pair. The obtained PCR products, containing a small 50-70 bp deletion but otherwise being identical in sequence to the target templates, were then cloned into the pCRII vector (Invitrogen BV, Leek, The Netherlands).
Quantitation was performed as follows. A master mix of the PCR reagents (2.0 U Dynazyme DNA polymerase, 5 l 10 ϫ DynaZyme reaction buffer, dNTP reaction mix at a final concentration of 200 M, 50 pmol each primer and water to a final volume of 48 l) was aliquoted into sample tubes, and a constant amount of the studied cDNA together with a serial dilution of control plasmid was added to the reactions. Thirty-five PCR cycles were performed. An aliquot of reaction mixture was electrophoresed in agarose gel and stained with ethidium bromide. A typical example is shown in Figure 1 . The bands were measured directly from agarose gels with the ImageMaster VDS densitometer and calculated with the ImageMaster 1D software from Amersham Pharmacia Biotech. The amount of studied mRNA was quantitated by determining graphically the point at which the amount of control molecules was equal to the target template. The results were correlated with the amount of ␤ -actin mRNA in each sample quantitated by Northern blot. The numbers of experiments done are presented in Figures 2-5 .
Results
Expression of CYP mRNAs in A549 Cells
Qualitative RT-PCR with gene-specific primers was performed to detect the general expression pattern of CYP mRNAs. As illustrated in Figure 6 , correct-size amplification products, matching those derived from human liver cDNA, were seen for CYPs 1A1, 1B1, 2B6, 2C8-19, 2E1, 3A5, and 3A7 in the A549 cells. A summary of the RT-PCR results is provided in Table 1 . CYP3A5 was the most abundantly expressed member of the CYP3A family, whereas CYP3A7 was observed in much lower quantities and CYP3A4 mRNA was missing altogether. CYP1A2, CYP2A6, CYP2A7, CYP2A13, CYP2F1, and CYP4B1 mRNAs were not detected at this level of sensitivity, which yielded clearly visible amplification products for each CYP in human liver or human alveolar macrophage (for CYP2F1 and CYP4B1) cDNA (data not shown). CYP2D6 amplification yielded multiple bands of different sizes, possibly reflecting the expression of pseudogenes and aberrantly spliced mRNAs (2, 30).
Induction of CYP1 and CYP3A mRNAs in A549 Cells
To determine whether individual CYP forms in the families CYP1 and CYP3A are inducible by xenobiotics, the concentrations of CYP1A1, CYP1B1, CYP3A4, and CYP3A5 mRNAs were measured by quantitative RT-PCR after exposing the A549 cells to well-defined chemical inducers. A 24-h exposure to TCDD (10 nM) caused a 56-fold increase in the amount of CYP1A1 (Figure 2) , whereas a similar treatment produced only a 2.5-fold induction of CYP1B1 mRNA (Figure 3 ). CYP1A1 and CYP1B1 mRNAs were not affected by treatment with either 10 M rifampicin, 10 M dexamethasone, or 1.5 mM phenobarbital. CYP3A4 mRNA was not present constitutively and its amount did not increase to detectable levels after exposure to any of the inducing compounds studied (PCN, clotrimazole, rifampicin, phenobarbital, dexamethasone, and TCDD). Interestingly, the amount of CYP3A5 mRNA was induced 8-fold and 11-fold by dexamethasone and phenobarbital, respectively, while PCN, clotrimazole, rifampicin, and TCDD did not cause any effect (Figure 4) .
Modulation of TCDD-Induced CYP1A1 and CYP1B1
The role of intracellular protein phosphorylation in CYP1A1 and CYP1B1 induction was assessed by culturing the A549 cells in the presence of TCDD and protein kinase or protein phosphatase inhibitors. An amount of 50 nM staurosporine (a protein kinase C inhibitor) and 50 M genistein (a tyrosine kinase inhibitor) blocked 79% and 65% of TCDD-elicited induction of CYP1A1, respectively ( Figure  5 ). The protein phosphatase inhibitors calyculin A (3 nM) and okadaic acid (10 nM) had minor effects on CYP1A1 induction, but slightly enhanced the induction of CYP1B1 mRNA. Genistein and staurosporine had negligible effects on CYP1B1 induction by TCDD ( Figure 5 ).
Discussion
The human adenocarcinoma cell line A549 is derived from alveolar epithelial type II cells, a cell type that expresses several CYP forms and also possesses metabolic activities toward xenobiotics. CYP proteins in type II cells include inducible CYP1A1 (9, 13, 31), CYP2B6 (31), CYP2E1 (31) , and CYP3A (14, 15, 32) (Table 1) . Functional epoxide hydrolase and ethoxyresorufin O-deethylase (EROD) activities have also been detected in these cells (33) . A549 cells have retained many of the morphologic and metabolic features of normal type II cells (20) . In earlier studies, A549 cells were shown to express at least CYP1A1, CYP1B1, and CYP2B6 enzymes (21, 22, 34, 35) . These cells are also able to form DNA adducts after B(a)P treatment (23) followed by an increase in p53 protein expression (36) . Both adduct formation and the p53 response are inhibited by the CYP1A1/CYP1B1 inhibitor ␣-naphthoflavone (36). Döhr and coworkers (21, 37) and Vogel and colleagues (38) have studied extensively the transforming growth factor-␤ 1 -mediated downregulation of TCDD-induced CYP1A1, CYP1B1, and EROD activity in A549 cells and they have also detected the expression of aryl hydrocarbon receptor (AHR) and AHR nuclear translocator (ARNT) in this cell line (21, 37) .
The objectives of this study were to determine comprehensively the expression pattern and induction of xenobiotic-metabolizing CYP mRNAs in the A549 cell line and to establish whether these characteristics resemble the ones found in alveolar type II cells. Qualitative and quantitative RT-PCR techniques were used because they are superior to conventional methods of mRNA detection owing to the great sensitivity and specificity of RT-PCR. Qualitative RT-PCR analysis showed that a number of major CYP forms are expressed in the A549 cells, and several individual CYPs are absent (Table 1, Figure 6 ). These data correlate well with earlier studies on in vivo pulmonary CYP expression. CYP1A1 has been shown to be inducible by cigarette smoking and it is mainly located in the peripheral lung (7-9, 13). Tobacco smoke-induced CYP1B1 mRNA has been found in bronchial cells (11) and alveolar macrophages (R. Piipari, unpublished data). CYP2B6 mRNA is consistently detected in the human lung (11, 24, 39) , and there is evidence for the presence of the corresponding protein as well (12, 31) . There are also indications for the presence of CYP2C isoforms in the human lung (12, 40) . Despite numerous studies, there is still controversy about CYP2D6 expression in the pulmonary tissue (12, 24, 30, (40) (41) (42) . It is likely that CYP2D6 mRNA is present in the lung as multiple splice variants (42), as corroborated by this and our previous study (24) . CYP2E1 expression has been established in several studies (12, (43) (44) (45) . We did not detect in the A549 cells CYP2F1 and CYP4B1 mRNAs that have been found in whole lung tissue (10, 24, 39, 46, 47) . In contrast to abundant hepatic expression of CYP3A4, this isoform seems to be of minor significance in the lung where it is expressed in only about 20% of the cases (15) . It appears that in analogy with many other extrahepatic tissues, CYP3A4 is replaced by CYP3A5 in the human lung (12, 14, 15, 24) .
The inducibility by chemicals of the major B(a)P activating CYP forms was assessed by quantitative RT-PCR. TCDD, a potent polycyclic aromatic hydrocarbon type inducer, clearly elevated the concentration of CYP1A1 mRNA (56-fold), whereas the increase in the amount of CYP1B1 mRNA was much more modest (2.5-fold), corroborating earlier findings in the same cell line (21, 37, 38) . CYP3A4 was not affected by any of the typical inducing compounds studied. A major finding of this study is the approximately 10-fold induction of CYP3A5 elicited by dexamethasone and phenobarbital. CYP3A5, the minor hepatic CYP3A isoform, is not induced in human liver (18, 19) , but there is evidence for its induction in human colon carcinoma cell lines (48) . The promoter region of the CYP3A5 gene contains functional glucocorticoid-responsive element halfsites that have been shown to mediate induction by dexamethasone (49) . The CYP3A4 gene is induced by binding of pregnane X receptor-retinoid X receptor (PXR-RXR) heterodimer to an everted repeat element (ER6) in the promoter area of the gene. However, the same heterodimer cannot activate the imperfect ER6 element found in the CYP3A5 gene (50) . This is supported by the present finding that PXR-activating compounds like rifampicin and clotrimazole do not induce CYP3A5 in A549 cells. It is therefore likely that the glucocorticoid receptor conveys CYP3A5 induction as postulated by Schuetz and coworkers (49) . These lines of evidence suggest that CYP3A5 induction is regulated in a tissue-specific manner in extrahepatic organs such as the lung and colon where this enzyme is abundantly expressed.
The role of intracellular protein phosphorylation on TCDD-induced CYP1A1 and CYP1B1 was determined using specific protein kinase and phosphatase inhibitors. The tyrosine kinase inhibitor genistein blocked CYP1A1 induction by TCDD but did not affect the inducibility of CYP1B1. A similar inhibition of CYP1A1 induction by (52) postulated that the action of genistein is due to a dual action of inhibition of tyrosine kinase and topoisomerase I. Also topoisomerase I inhibitor camptothecin blocks CYP1A1 induction by TCDD (52, 55) . According to Gradin and coworkers (51), the target for genistein action is the region of AHR harboring its ligand-binding domain. It was postulated that genistein inhibited ligand-induced release of hsp90 from the AHR (51).
The lack of effect of genistein on CYP1B1 induction observed here indicates that its induction by TCDD is less dependent on AHR. This is supported by the fact that the CYP1B1 gene promoter is structurally and functionally similar to the promoters of constitutively expressed genes (56) . The protein kinase C (PKC) inhibitor staurosporine inhibited CYP1A1 induction but did not affect CYP1B1 induction. This is in agreement with findings that PKC inhibitors block the AHR-mediated induction of CYP1A1 (54, (57) (58) (59) (60) (61) . The mechanism of PKC action on TCDD-elicited induction is controversial with conflicting reports in the literature. It seems that PKC inhibitors exert their action either by obstructing the DNA binding activity of AHR (54, 57) or by blocking the formation of a functional transcriptional complex capable of transactivating the CYP1A1 promoter without affecting DNA binding (59, 61, 62) . The lack of effect of PKC inhibitors on CYP1B1 induction in the A549 cells provides further evidence of greater independence of CYP1B1 from the AHR. The serine/threonine protein phosphatase inhibitors calyculin A and okadaic acid enhanced CYP1B1 induction slightly but did not alter CYP1A1 induction. Previously these inhibitors (3 nM calyculin A, 50 nM okadaic acid) were shown to enhance the AHR-mediated induction in mouse Hepa-1 cells by affecting a step subsequent to xenobiotic response element (XRE) binding (63) . There is also a report where 20 nM okadaic acid had no effect on polycyclic aromatic hydrocarbon induction of CYP1A1 mRNA in rat primary hepatocytes (60) . Phosphatase treatments of AHR/ARNT have been shown to abolish the ability of the receptor complex to bind at XRE (54, 64, 65) .
In conclusion, these results show that the A549 lung adenocarcinoma cell line is a valuable model for studies on human pulmonary xenobiotic metabolism. This cell line expresses many of the CYPs involved in activation of pulmonary toxicants and it has also retained the inducibility of CYP1 isoforms. The observed induction of CYP3A5 by phenobarbital and dexamethasone in this cell line is intriguing because this isoform is the major CYP3A form in the human lung. Current studies in our laboratory are aimed at assessing whether CYP3A5 is induced by other glucocorticoids, including the ones extensively used for the treatment of obstructive airway diseases, and ascertaining the mechanisms of this induction in the A549 cells.
